Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 32YB4 | IM |
Administration via intramuscular route; Above recommended age; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 35-year-old female patient who received MMR (Priorix) (batch number 32YB4, expiry date 01-DEC-2026) for prophylaxis. On 17-APR-2025, the patient received Priorix (intramuscular). On 17-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Administration via intramuscular route) and inappropriate age at vaccine administration (Verbatim: Above recommended age). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-APR-2025 The pharmacist contacted to request data and recommendations after a 35 year old female patient which was accidentally administered a dose of Priorix via intramuscular route which led to inappropriate age at vaccine administration and subcutaneous injection formulation administered by other route. They stated the patient had received a series in 1991 and a booster in 2001. The vaccine administration facility was the same as primary reporter.